Poster Session B
Breast cancer
B1 – B78
- B1: UK national survey on the use of Adjuvantonline as a decision making tool in early breast cancer (www.adjuvantonline.com)
- B2: Improved methods of detection, and prognostic significance, of vascular invasion in breast cancer
- B3: Basal-like and triple negative breast cancer frequently occur in Nigerian women
- B4: Prognosis of brain metastasis in breast cancer patients, with respect to receptor status
- B5: High throughput analysis of breast cancer epigenome
- B6: Scotin is required for ER-stress mediated apoptosis and is associated with good prognosis in breast cancer
- B7: The cocaine and amphetamine-regulated transcript (CART) is an independent prognostic factor in lymph node-negative breast cancer and predicts tamoxifen response
- B8: An optical proteomic profile of the ErbB family in solid tumours exposed to tyrosine kinase inhibitors (TKIs)
- B9: Borderline HER2 protein positive breast cancers have similar patient outcome regardless of HER2 gene amplification status
- B10: Primary leiomyosarcoma of the male breast: a case report
- B11: Is tissue the issue? The impact of biopsy confirmation of metastases in breast cancer
- B12: Human p53 isoforms and cancer
- B13: p53β and p53γ isoform expression may abrogate poor prognosis in patients with p53 mutant breast cancer
- B14: Young onset breast cancer patients who develop distant metastases within 12 months of primary diagnosis
- B15: The experience of spiritual healing for women with breast cancer
- B16: Treatment of HER2+ breast cancer in routine practice – review of testing and use of adjuvant trastuzumab across a cancer network
- B17: UK and European pattern of care in advanced breast cancer patients after exposure to anthracycline and taxane
- B18: Abstract withdrawn
- B19: Ipsilateral breast tumour relapse: local recurrence versus new primary and the effect of whole breast radiotherapy on the rate of new primaries
- B20: Concurrent trastuzumab and radiotherapy – retrospective single institution study of acute cardiac toxicity
- B21: Single dose radiotherapy during surgery for breast cancer patients where external beam radiation was not feasible: results after 3 years of follow-up
- B22: A multi centre prospective longitudinal study establishing level II evidence of health related quality of life after types of immediate latissimus dorsi (LD) breast reconstruction
- B23: Use of local anaesthetics in breast cancer surgery
- B24: Re-operation after breast conservation surgery - multifocal breast cancer
- B25: Predicting benefit from fulvestrant in pretreated metastatic breast cancer (MBC) patients
- B26: A randomised, phase III trial exploring the effects of neoadjuvant sequential aromatase inhibitor treatment in post-menopausal women locally advanced breast cancer (LABC)
- B27: Pragmatism in breast cancer clinical trial design encouraged wider participation of centres yet yielded a homogenous patient profile
- B28: Altered tissue 3’-Deoxy-3’-[18F]Fluorothymidine Pharmacokinetics in human breast cancer following Capecitabine treatment detected by positron emission tomography
- B29: Investigating the association between ethnicity and survival from breast cancer using routinely collected health data: challenges and potential solutions
- B30: Training health professionals to deliver an intervention to promote early presentation of breast cancer: a pilot study in the NHS Breast Screening Programme
- B31: The spatial distribution of radiodense breast tissue: a longitudinal study
- B32: Breast cancer incidence, treatment and survival in ethnic groups in south east England
- B33: Abstract withdrawn
- B34: The risk of breast cancer among women who start tobacco smoking as teenagers
- B35: Randomised controlled trial of mammographic screening in young women: updated results on incidence and mortality
- B36: Successful paired blood and saliva DNA in high throughput genotyping and genome-wide association studies
- B37: Age of onset in hereditary and familial breast cancer
- B38: Involving patients in clinical trial design: the experience of the UK Ibreast early breast cancer follow-up trial
- B39: Cognitive behaviour therapy for menopausal symptoms following breast cancer treatment
- B40: The financial costs and consequences of cancer for patients and their families: a postal survey of patients with breast, lung, and prostate cancer in Ireland
- B41: Associations between the financial impact of cancer and depression, anxiety and stress in individuals with breast, lung and prostate cancer
- B42: Women’s comments on their breast cancer and treatment experiences: 5 years on (The START trial CRUK/96/001)
- B43: The psychological impact of the diagnosis and treatment of DCIS; (BASO-DCISII Trial (CRUK05/005)
- B44: Exploring the breast cancer experiences, needs and preferences of women aged 70 years and over: study findings
- B45: A prospective, longitudinal study to investigate the impact of changes in service provision for the follow-up of women (over 50 years) with primary breast cancer
- B46: Integration, analysis and meta-mining of data to aid disease diagnosis, prognosis and treatment response
- B47: Biological effects of the S-adenosylhomocysteine hydrolase inhibitor 3-deazaneplanocin (DZNep) and analogues in breast cancer cell lines
- B48: ADAM Processing of TMEFF1, a potential regulator of TGF-ß signalling in breast cancer
- B49: Bidirectional receptor crosstalk in breast cancer: implications for future treatment strategies
- B50: Examining a role for histone methyltransferases and demethylases in estrogen-dependent breast cancer
- B51: STAC2 expression predicts worse outcome in basal-like breast cancer
- B52: Prognostic value of FOXP3+ T regulatory cell expression in breast cancer
- B53: Loss of protein folding gene expression in human tumours
- B54: Expression of high molecular weight tenascin-C isoforms is associated with breast carcinomas in young women
- B55: Characterisation of mouse p53 isoforms
- B56: An in vitro/vivo shRNA screen to identify novel breast cancer metastasis suppressor genes
- B57: Using high-throughput approaches to dissect triple negative breast cancer
- B58: High DNA content is associated with poor prognostic features in primary breast cancer
- B59: Evaluation of der(1;16)(q10;p10) chromosome rearrangement in breast cancer
- B60: Expression levels of Src kinase family members (SKFMs) in human breast tissue
- B61: TRAIL-R1-specific therapeutic agents in combination with doxorubicin selectively target primary breast tumour cells for apoptosis
- B62: Determination of HER2 status in invasive breast carcinomas using tissue microarray
- B63: BubR1 as a predictive marker of anthracycline sensitivity in the BR9601 trial
- B64: Expression of DPPA3 (STELLA), EDR1 (PHC1), GDF3, and NANOG, putative stem cell genes on chromosome 12, in breast carcinoma: a preliminary study
- B65: Evaluation of KI67 as a marker of Luminal B tumours in breast cancer
- B66: Detection of Akt activation in early breast cancer using proximity ligation assays
- B67: Expression levels of ERα and co-factors in early breast cancer
- B68: Using formalin fixed paraffin embedded (FFPE) core biopsy samples for molecular marker studies of breast cancer: Feasibility study of copy number and gene expression analysis
- B69: Columnar cell lesions are the early precursors of some forms of invasive breast carcinoma: a new genetic map for the evolutionary pathway of low nuclear grade breast neoplasia (LNGBN) family
- B70: Cell cycle phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer
- B71: Genome-wide SNP–LOH analysis of intracystic papillary carcinoma of the breast
- B72: Effects of ∆133 isoform of p53 on the growth and metastasis ability of the breast cancer cell MCF7 in xenograft models
- B73: Inter-centre variability of left ventricular ejection fractions (LVEF) measured by multigated aquisition (MUGA) scan in early breast cancer patients for adjuvant trastuzumab therapy: potential impact on multi-centre studies and defining lower limit of normal
- B74: An integrated web based pathology database to facilitate the annotation of tissue banked samples with high quality pathological and clinical data
- B75: Comparison of rates of febrile neutropaenia using FEC100/Docetaxel100 chemotherapy in breast cancer patients with and without primary GCSF prophylaxis
- B76: The clinical feasibility of assessing cardiac function in patients receiving trastuzumab for the adjuvant treatment of breast cancer
- B77: Macrophages and tumour revascularization following treatment with vascular disrupting agents
- B78: Effects of phenformin on establishment and growth of MCF7 tumour xenografts
